Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Molecular Predictors of Lung Cancer Behavior. (SPORE)

Multiple Cancer Types

Lung, Non Small Cell, Small Cell
N/A
Maldonado, Fabien
NCT00898313
VICCTHO0398

A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer

Multiple Cancer Types

This is a multicenter, open-label, Phase 1 study of ABBV-011 given as a single agent and in combination with budigalimab (ABBV-181) in participants with relapsed or refractory small cell lung cancer (SCLC). The study consists of 4 parts: Part A is a single-agent ABBV-011 dose regimen finding cohort; followed by Part B, a single-agent ABBV-011 dose expansion cohort; and then Part C, an ABBV-011 and budigalimab (ABBV-181) combination escalation and expansion cohort; Part D, single-agent ABBV-011 dose-evaluating cohort for Japan.
Lung, Phase I, Small Cell
I
Lehman, Jonathan
NCT03639194
VICCTHOP2092

Ifetroban in Treating Patients with Malignant Solid Tumors at High Risk of Metastatic Recurrence

Multiple Cancer Types

This phase II trial studies the side effects of ifetroban in treating patients with malignant solid tumors that are at high risk of coming back after treatment (recurrent) and spreading throughout the body (metastatic). Platelets are a type of blood cells that help with clotting. Cancer cells stick to platelets and ride on them to get to different parts of the body. Drugs, such as ifetroban, may help these platelets become less "sticky," and reduce the chance of cancer cells spreading to other places in the body.
Breast, Esophageal, Gastric/Gastroesophageal, Lung, Non Small Cell, Pancreatic, Small Cell
II
Reid, Sonya
NCT03694249
VICCMD1854

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: